Dose intensification using combination alkylating agents and autologous bone marrow support in the treatment of primary and metastatic breast cancer: a review of the Duke Bone Marrow Transplantation Program experience.
Peters
W P
WP
Duke University Medical Center, Durham, North Carolina 27710.
D000477:Alkylating Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000379:methods*; D001943:Breast Neoplasms / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009657:North Carolina
D000477:Alkylating Agents